Navigation Links
Results with newer bladeless LASIK equivalent to standard microkeratome LASIK

A Mayo Clinic study comparing femtosecond (bladeless) and mechanical microkeratome LASIK surgeries has found equal results from both types six months post-surgery, using a variety of vision and eye health measurements. The study's findings will be presented next week in three abstracts at the Association for Research in Vision and Ophthalmology meeting in Fort Lauderdale, Fla.

LASIK (Laser-assisted in situ keratomileusis) involves treating nearsightedness, farsightedness or astigmatism by reshaping the eye's cornea to alter the way the eye refracts light. LASIK involves creating a flap, removing a defined amount of corneal tissue by an excimer laser, and replacing the flap. In standard LASIK with a mechanical microkeratome, the flap is created by a blade; in bladeless LASIK, the newer type, the flap is created by a femtosecond laser.

"At six months after surgery, there are no differences between the eyes that had bladeless or microkeratome LASIK with respect to visual acuity (vision as measured by reading an eye chart), contrast sensitivity (ability to discriminate bright objects from dark objects), or in perception of stray light or glare, such as the glare from oncoming headlights," says Sanjay Patel, M.D., Mayo Clinic ophthalmologist and study investigator.

Given the equivalent findings thus far in eye health and vision between the two types of LASIK, Dr. Patel slightly prefers bladeless LASIK due to its potential safety, which was not measured in his study. "I'd say the short-term outcomes are equal and the risks are, in theory, less with the bladeless technique, although our study was not designed to compare risks," he says. "Bladeless LASIK is potentially safer because of its computer-controlled precision, the ability to visualize the flap being created, and to stop the procedure whenever necessary. That said, however, the risk of complications with a traditional, microkeratome blade is very small: some vision loss from surgery with a microkeratome blade occurs in well under 1 percent of all cases. The long-term risks of either procedure, however, are unknown, and defining them is the primary purpose of our study."

The study followed 20 patients who received LASIK for nearsightedness or astigmatism. Each patient was treated with microkeratome LASIK in one eye and bladeless LASIK in the other eye. The researchers found no difference in subbasal nerve density between types of surgery, though the density decreased after both treatments compared to density before LASIK. Corneal sensitivity did not differ between microkeratome and bladeless LASIK. Subbasal nerve density and corneal sensitivity do not impact vision, but rather the potential to heal from a scratch or other injury to the eye. High-contrast visual acuity, the capability to see fine details, and contrast sensitivity, the ability to perceive contrast in objects and their environments, also did not differ between LASIK types. The researchers found corneal backscatter was greater with bladeless LASIK for the first three months after surgery, yet the patients perceived no difference in vision after three months between their eyes treated with bladeless or microkeratome LASIK. Backscatter is haziness in the cornea that is usually invisible to the naked eye and is identified through testing in a physician's office. Cell densities in all layers of the cornea also did not differ between the LASIK surgeries.

The ultimate goal of the Mayo Clinic study of microkeratome versus bladeless LASIK is to obtain long-term information about patients' vision and eye health five years following surgery. The results presented now represent the first six months of findings.


'"/>

Source:Mayo Clinic


Related biology news :

1. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
2. Combating anthrax: Results of study published this month as researchers look for a better vaccine
3. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
4. Carnegie Mellon U. transforms DNA microarrays with standard Internet communications tool
5. Setting the standard for computer models of life
6. DOE JGI sets gold standard for metagenomic data analysis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2017)... Florida , April 17, 2017 NXT-ID, ... technology company, announces the filing of its 2016 Annual Report on ... and Exchange Commission. ... on Form 10-K is available in the Investor Relations section of ... as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
Breaking Biology Technology: